Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Status:
Active, not recruiting
Trial end date:
2022-06-27
Target enrollment:
Participant gender:
Summary
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching
from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.